Immix Biopharma Enters Underwriting Agreement with Morgan Stanley
I'm PortAI, I can summarize articles.
Immix Biopharma has entered an underwriting agreement with Morgan Stanley to issue over 19 million shares, priced at $5.10 each, aiming to raise approximately $93.7 million. The closing is expected on December 9, 2025. This move is part of a strategy to strengthen the company's capital and enhance its market position. Analysts rate IMMX stock as a Buy with a $8.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments